Abstract: Described is a garment (10) comprising an integrated first pocket (55) into which the garment (10) may be packed, when not in use and wherein the first pocket (55) comprises an opening (180) arranged at the lower end of the garment (10).

Abstract: A novel IgG4 isotype anti-KIR antibody, novel formulations of this and other IgG4 anti-KIR antibodies, and methods of using such formulations are provided. Also described are compositions, formulations, dosages, and administration regimens suitable for NK cell activation and therapeutic applications of anti-KIR antibodies, as well as kits comprising one or more anti-KIR antibodies with instructions for use in treating cancer.

Abstract: The present invention provides isolated anti-human NKG2D monoclonal antibodies useful for therapeutic applications in humans. Typically, the antibodies are fully human or humanized to minimize the risk for immune responses against the antibodies when administered to a patient. Preferred antibodies include human monoclonal antibodies MS and 21F2. As described herein, other antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules, can be designed or derived from such antibodies.

Abstract: A novel IgG4 isotype anti-KIR antibody, novel formulations of this and other IgG4 anti-KIR antibodies, and methods of using such formulations are provided. Also described are compositions, formulations, dosages, and administration regimens suitable for NK cell activation and therapeutic applications of anti-KIR antibodies, as well as kits comprising one or more anti-KIR antibodies with instructions for use in treating cancer.

Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.

Abstract: A fuel supply line system used for a gas turbine, including: fuel gas control valves used for controlling delivery to the gas turbine; a first line used for connecting the fuel gas source to the control valves; a second line used for connecting the control valves to the gas turbine; a monitoring device, configured to be used for determining the pressure inside the pipe at the outlet of the second line near said control valve; and a controller, configured to reduce the effective flow area of the pressure control valves or close the control valves when the determined pressure inside the pipe of the second line is greater than a predetermined pressure.

Abstract: The present invention relates to a method and a device for the simultaneous compression and characterization of ultrashort laser pulses. An embodiment of the method comprises applying predetermined spectral phases to the pulse to be characterized so as to perform a dispersion scan; applying a nonlinear process to the pulse to be characterized; measuring the resulting signal from the application of the predetermined spectral phases and nonlinear process; applying a numerical iterative algorithm to the measured signal to retrieve the spectral phase of the pulse to be characterized. A few cycle laser pulse may be negatively chirped with a pair of DCM, the controllable amount of positive dispersion may be provided by a pair of glass wedges, one of them being translated for dispersion or phase control, and the frequency spectrum may be measured as well as also frequency resolved the dispersion dependent second-harmonic of the signal being phase modulated.

Abstract: The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies, and to cells that express such antibodies. antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1- and CD161-expressing cells play a role in disease pathogenesis.

Abstract: The invention relates to a photovoltaic cell, comprising a plate shaped substrate of a semiconductor material with a solar face and a connection face, a first volume of the substrate adjacent to the solar face is doped with a first polarity, the second volume is doped with a second polarity and the volumes are separated by a pn-junction, a number of apertures in the substrate extending between both faces and in which a plug has been positioned of which a part is conducting, contact tracks at the solar face of the substrate connected with the first volume and the conducting part of the plug, first contacts at the connection face of the substrate connected with the conducting part of the plug and second contacts located at the connection face of the substrate connected with the second volume, wherein the specific electrical conductivity of the plug decreases from its centre to the contact face with the substrate.

Abstract: Described are methods of treating viral disease using compounds that block inhibitory NK cell receptors, thereby reducing their inhibition of NK cell cytotoxicity in killing infected target cells. In one embodiment, the compound is an antibody binding, for example, one or more of the human KIR2DL1, KIR2DL2, and KIR2DL3 receptors. In another embodiment, the method further comprises administering a therapeutic antibody or fusion protein which binds an antigen expressed on cells infected with the virus.

Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.

Abstract: The present invention provides isolated anti-human NKG2D monoclonal antibodies useful for therapeutic applications in humans. Typically, the antibodies are fully human or humanized to minimize the risk for immune responses against the antibodies when administered to a patient. Preferred antibodies include human monoclonal antibodies MS and 21F2. As described herein, other antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules, can be designed or derived from such antibodies.

Abstract: The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies, and to cells that express such antibodies. antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1- and CD161-expressing cells play a role in disease pathogenesis.

Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.

Abstract: Systems and methods are described in the present disclosure for determining the location and orientation of an object placed on a surface. One such system, among others, includes an optical device physically supported by an object at a fixed position with respect to a reference point of the object. The system also includes a surface upon which the object can be placed. A reference pattern, which is applied to the surface, includes an array of markings visible to the optical device. The array of markings includes encoded location information and orientation information. In addition, the system includes a processing device in communication with the optical device. The processing device is configured to calculate the location and orientation of the reference point of the object with respect to the surface.

Abstract: The present invention provides isolated anti-human NKG2D monoclonal antibodies useful for therapeutic applications in humans. Typically, the antibodies are fully human or humanized to minimize the risk for immune responses against the antibodies when administered to a patient. Preferred antibodies include human monoclonal antibodies MS and 21 F2. As described herein, other antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules, can be designed or derived from such antibodies.

Abstract: The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies and to cells that express such antibodies. Antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1-and CD161-expressing cells play a role in disease pathogenesis.

Abstract: A regulating device for regulating the course of a gas turbine plant has at least one sensor for sensing a measurement variable and for outputting a measurement signal which represents the measurement variable; at least one adjusting system for influencing air and/or fuel supply to a combustion chamber of the gas turbine plant on the basis of a correcting variable; and a regulator connected to the at least one sensor so as to receive the measurement variable and to the at least one adjusting system for outputting the correcting variable, the regulator being designed to determine the correcting variable on the basis of the measurement variable received and its deviation from a pilot variable. At least one sensor is designed to sense the variation in time of at least one burner or combustion chamber parameter as measurement variable.

Abstract: A novel IgG4 isotype anti-KIR antibody, novel formulations of this and other IgG4 anti-KIR antibodies, and methods of using such formulations are provided. Also described are compositions, formulations, dosages, and administration regimens suitable for NK cell activation and therapeutic applications of anti-KIR antibodies, as well as kits comprising one or more anti-KIR antibodies with instructions for use in treating cancer.

Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.